1 / 8

Supplementary Figure 1

Supplementary Figure 1. A. SU-DHL4. AKT-CA. pUSE. Myr -AKT. AKT. Endogenous AKT. Tub. B. SU-DHL4 pUSE. 50. SU-DHL4 AKT-CA. *. 40. *. % dead cells. 30. 20. 10. 0. 0. 10. 15. 25. 40. [ Panobinostat ] ( nM ). Supplementary Figure 2. A. B. C. 100. SU-DHL4. 80. *.

jereni
Download Presentation

Supplementary Figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplementary Figure 1 A SU-DHL4 AKT-CA pUSE Myr-AKT AKT Endogenous AKT Tub B SU-DHL4 pUSE 50 SU-DHL4 AKT-CA * 40 * % dead cells 30 20 10 0 0 10 15 25 40 [Panobinostat] (nM)

  2. Supplementary Figure 2 A B C 100 SU-DHL4 80 * SU-DHL4 60 SU-DHL16 Viability (% controls) OCI-LY18 1.2 40 HBL-1 1.0 0.8 0.9 CI 20 0.6 0.4 0.6 0.2 1.0 CI 0 0 1.0 0.8 Jeko-1 C IPI SB 0 0.2 0.4 0.6 0.8 1.0 CAL 0.3 CI 0.6 0.8 SB/CAL SB/IPI Fractional Effect 0.4 OCI-LY18 0.6 D E F CI 0.2 0 0.4 0 0 0.2 0.4 0.6 0.8 1.0 0.2 1.0 0 0.2 0.4 0.6 0.8 1.0 0 Fractional Effect 0.8 Fractional Effect 0 0.2 0.4 0.6 0.8 1.0 0.6 CI Fractional Effect 0.4 HBL-1 0.2 SU-DHL16 0 0 0.2 0.4 0.6 0.8 1.0 Fractional Effect Fractional Effect

  3. Supplementary Figure 3 OCI-LY7 4h 8h BZ PB BZ PB C BZ PB C BZ PB p-AKT AKT p21 Ac-H3 H3 Ac-H4 p-H2A.X Tub

  4. Supplementary Figure 4 B C A SU-DHL4 SU-DHL16 SU-DHL4 D BZ * * 80 * shGFP PB * shBim 60 Mcl-1 * 80 * % dead cells shGFP Bcl-2 % dead cells * 40 shBim 60 Viability (% controls) * Bcl-xL 20 40 Tub 0 0 250 500 1000 2000 20 shGFP [BEZ235] nM [Panobinostat] nM shBim 0 0.0 12.5 25.0 50.0 SU-DHL16 SU-DHL4 E 100 shBim shGFP BZ PB BZ PB C BZ PB C BZ PB 50 - - + + - - + + Bim 0 C-casp3 C BZ PB BZ/PB C BZ PB BZ/PB Tub

  5. Supplementary Figure 5 Lysates BZ PB IGG C BZ PB Bcl-2 IP: Bim Bcl-xL Bim Mcl-1 IP: Bak Bcl-xL Bak Mcl-1 Bcl-2 IP: Bax Bcl-xL Bax

  6. Supplementary Figure 6 A B 100 shGFP 100 shBak 80 shGFP shBax shBak 80 60 shBax Viability (% controls) 60 40 Viability (% controls) 40 20 * * 20 * * * 0 0 6.25 12.5 25.0 50.0 0 [Panobinostat] nM 0 250 500 1000 2000 [BEZ235] nM C D 100 100 shGFP shGFP * * shBak * 80 shBak * * 80 shBax shBax * 60 60 % dead cells % dead cells 40 40 20 20 0 0 6.25 0 250 500 1000 2000 0 12.5 25.0 50.0 [BEZ-235] nM [Panobinostat] nM

  7. Supplementary Figure 7 50 100 RM HS-5 CM 40 B A 75 30 Viability (% controls) 50 * % dead cells * 20 25 10 - - - + + + - - - + + + 0 - - - - - - + + + + + + BZ 0 PB C Doxo C Doxo HBL-1 SU-DHL4 OCI-LY18 SU-DHL4 HBL-1 RM CM

  8. 0 Supplementary Figure 8 50 C BZ PB Treatment intervals (days) BZ/PB 25 Weight (g) 0 10 20 30 40 50 60 70

More Related